SOPHiA GENETICS SA Hits New 52-Week High of USD 6.74

SOPHiA GENETICS SA has reached a significant milestone by hitting a new 52-week high of USD 6.74 on July 21, 2026. This achievement marks a notable increase from its 52-week low of USD 2.92, reflecting a robust one-year performance of 35.42%, significantly outperforming the S&P 500, which recorded a 19.09% gain during the same period. As a microcap company in the Software Products industry, SOPHiA GENETICS SA has a market capitalization of USD 337 million. Despite its recent price surge, the company remains in a loss-making position, with a negative return on equity of -159.46%. The stock's price-to-book ratio stands at 7.14, indicating a premium valuation relative to its book value. Investors may find the company's financial metrics noteworthy, particularly its debt-to-equity ratio of -0.42, which suggests a unique capital structure. With no dividend yield currently offered, SOPHiA GENETICS SA continues to focus on growth within its sector.